Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis.

AIM

To evaluate the differences in outcomes between ABO-incompatible (ABO-I) liver transplantation (LT) and ABO-compatible (ABO-C) LT.

METHODS

A systematic review and meta-analysis were performed by searching eligible articles published before No-vember 28, 2016 on MEDLINE (PubMed), EMBASE, and Cochrane databases. The primary endpoints were graft survival, patient survival, and ABO-I-related complications.

RESULTS

Twenty-one retrospective observational studies with a total of 8247 patients were included in this meta-analysis. Pooled results of patient survival for ABO-I LT were comparable to those for ABO-C LT. However, ABO-I LT showed a poorer graft survival than ABO-C LT (1-year: OR = 0.66, 95%CI: 0.57-0.76, < 0.001; 3-year: OR = 0.74, 95% CI 0.64-0.85, < 0.001; 5-yearr: OR =0.75, 95%CI: 0.66-0.86, < 0.001). Furthermore, ABO-I LT was associated with more incidences of antibody-mediated rejection (OR = 74.21, 95%CI: 16.32- 337.45, < 0.001), chronic rejection (OR =2.28, 95%CI: 1.00-5.22, = 0.05), cytomegalovirus infection (OR = 2.64, 95%CI: 1.63-4.29, < 0.001), overall biliary complication (OR = 1.52, 95%CI: 1.01-2.28, = 0.04), and hepatic artery complication (OR = 4.17, 95%CI: 2.26-7.67, < 0.001) than ABO-C LT. In subgroup analyses, ABO-I LT and ABO-C LT showed a comparable graft survival in pediatric patients and those using rituximab, and ABO-I LT showed an increased acute cellular rejection in cases involving deceased donor grafts.

CONCLUSION

Although patient survival in ABO-I LT was comparable to that in ABO-C LT, ABO-I LT was inferior to ABO-C LT in graft survival and several complications. Graft survival of ABO-I LT could be comparable to that of ABO-C LT in pediatric patients and those using rituximab.